Assessment of Executive Functions After Covid-19

Covid19 Clinical Trial

Official title:

May Covid-19 Impair Executive Functions? A Crossectional Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04771624
• Other study ID #: 21022021
• Status: Completed
• Start date: October 30, 2020
• Est. completion date: November 1, 2021

Study information

• Verified date: November 2021
• Source: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

As it is evident that Covid-19 may have some impacts on cognition, the primary aim of this study is to investigate -if any- deficits of attention, working memory and executive functions after Covid-19.

Description:

Since Covid-19 (Coronavirus Disease-2019) was declared as a pandemic by the World Health Organization (WHO) on December 31, 2019, it is still widespread and deadly. As an ongoing pandemic, it has led to a panic and then a controlled fear in societies. In many studies, neuropsychological deficits were observed in Covid-19 patients both during the illness and after recovery. A recent study found that impairment in cognitive functions continued after recovery of Covid-19, and it was associated with peripherical inflammatory markers, such as C-Reactive Protein (CRP). CRP, as a peripherical inflammatory marker, has been proven to be inversely related to serum levels of the brain-derived neurotrophic factor (BDNF), an important neurotrophin in the growth and differentiation of neurons. In this study, attention, working memory and executive functions of Covid-19 patients at post-covid period and its relation with the severity of the disease will be investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: November 1, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Covid-19 patients:

• Diagnosed as Covid-19 by RT-PCR at least 60 days but not more than 90 days ago

• Asymptomatic at the moment

• Not having any other general medical, neurological or psychiatric conditions except Covid-19 at the time of acute infection

Healthy subjects:

• Not having any of Covid-19 symptoms at the testing time point

• Not having any general medical, neurological or psychiatric condition

Exclusion Criteria:

Covid-19 patients:

• Diagnosed as Covid-19 by RT-PCR less than 60 days or more than 90 days ago

• Having any symptom of acute phase of Covid-19

• Having any other general medical, neurlogical or psychiatric contidions

Healthy subjects:

• Having any of Covid-19 symptoms at the testing time point

• Having any general medical, neurological or psychiatric condition

Related Conditions & MeSH terms

• Cognitive Impairment
• COVID-19
• Covid19

Locations

Country	Name	City	State
Turkey	Saglik Bilimleri Üniversitesi Gazi Yasargil Training and Research Hospital	Diyarbakir

Sponsors (1)

Lead Sponsor	Collaborator
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, Fromson JA, Xu Y, Liu X, Xu H, Zhang T, Lu Y, Chen X, Hu H, Tang Y, Yang S, Zhou H, Wang X, Chen H, Wang Z, Yang Z. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: A mixed-method study. Brain Behav Immun. 2020 Aug;88:17-27. doi: 10.1016/j.bbi.2020.05.038. Epub 2020 May 19. — View Citation

Wilson BA, Betteridge S, Fish J. Neuropsychological consequences of Covid-19. Neuropsychol Rehabil. 2020 Oct;30(9):1625-1628. doi: 10.1080/09602011.2020.1808483. — View Citation

Zhou H, Lu S, Chen J, Wei N, Wang D, Lyu H, Shi C, Hu S. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020 Oct;129:98-102. doi: 10.1016/j.jpsychires.2020.06.022. Epub 2020 Jun 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neuropsychological test scores	Neuropsychological test scores of Covid-19 patients in comparison with healthy control subjects	Up to 90 days
Secondary	Severity of the disease	Neuropsychological test score changes according to the disease severity of Covid-19 patients	Up to 90 days